Publication / Source: Bioanalysis 2(5)
Authors: Schmitt M, Lazar V
“Toward this goal of harmonizing worldwide activities in personalized cancer medicine and tailored therapy, a new cancer research consortium, the Worldwide Innovative Network in Personalized Cancer Medicine was founded in July 2009 … to promote personalized cancer medicine and cancer treatment…”
One of the major future challenges in oncology will be the early diagnosis and individualized, tailored care of cancer patients. Tailored cancer care is integrated into the concept of cancer medicine with the aim of gaining information about a patient’s gene and/or protein expression profile or obtaining functional imaging modifications, in order to identify patients at risk. Yet, to achieve personalized treatment of cancer, we need meaningful biomarkers (signatures) for characterizing of cancer subgroups, determining prognosis, predicting response to therapy and foreseeing severe toxicity related to treatment [1–3].